Newsroom - Press Releases - Tetra Bio-Pharma

2020 2019 2018 2017 2016

02/27/2020

Tetra Bio-Pharma Enters into Co-Development Agreement with MAKScientific

02/25/2020

Tetra Bio-Pharma Provides Additional Information on CAUMZ Following Type B Meeting with USA FDA

02/24/2020

Tetra Bio-Pharma Provides Additional Information on QIXLEEF Following Letter of Advice & Type B Meeting with USA FDA

02/20/2020

Tetra Bio-Pharma Inc. Announces Listing of Warrants

02/20/2020

Tetra Bio-Pharma Initiates a Proof of Concept Clinical Trial for its Ophthalmic Drug in Dogs

02/18/2020

Tetra Bio-Pharma Appoints Sylvain Chrétien as President

02/13/2020

Tetra Bio-Pharma Enters into Manufacturing Agreement with Vitiprints LLC for CAUMZ™ and HCC011

02/13/2020

Tetra Bio-Pharma Announces Closing of Bought Deal Financing

02/03/2020

Tetra Bio-Pharma Announces CAUMZ Program Update AND Expansion of Market Potential Following Type B Meeting with USA FDA

01/31/2020

Tetra Bio-Pharma Receives Favorable Response Following Type B Meeting with USA FDA for CAUMZ™

01/28/2020

Tetra Bio-Pharma Provides an Update on Its Veterinary Ophthalmic Clinical Study with PPP003

01/27/2020

Tetra Bio-Pharma Announces Upsizing of Previously Announced Offering

01/22/2020

TETRA BIO-PHARMA - PRESS RELEASE CORRECTION

01/21/2020

Tetra Bio-Pharma Announces $10.0 Million Bought Deal Offering

01/20/2020

Tetra Bio-Pharma Provides Update on its Commercialization Plan for its OTC DIN and NHP Product Programs

01/17/2020

Tetra Bio-Pharma Granted Two OTC Drug Identification Numbers (DIN) by Health Canada

01/13/2020

Tetra Bio-Pharma Receives Favorable Letter of Advice from USA FDA for QIXLEEF